Janssen Loses Remicade Patent Case To Pfizer, Celltrion
A recipe related to Janssen Biotech Inc.'s blockbuster immunosuppressant Remicade was too obvious for any competitor to have legally infringed a patent on it, a Massachusetts federal judge ruled Tuesday, allowing Pfizer...To view the full article, register now.
Already a subscriber? Click here to view full article